

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma

SUPPLEMENTARY MATERIALS




Supplementary Figure 1: Chemical structure of TAK-580.



Supplementary Figure 2: Time-dependent effect of TAK-580 in MM cells. KMS-11 and U266 cells were cultured with TAK- $580(20 \,\mu\text{M})$  for 24 or 48 h. The cell number and viability were assessed with trypan blue exclusion. Data are the mean  $\pm$  SD of six replicate wells.

## **KMS-11**



Supplementary Figure 3: The combination of TAK-580 and BTZ triggers synergistic anti-MM activity. (A) (Left panel): The graph represents ratios of p-FOXO3 density relative to  $\beta$ -Actin in Figure 4D. (Right panel): The graph represents ratios of p-FOXO3 density relative to  $\beta$ -Actin in Figure 4D. (Right panel): The graph represents ratios of p-FOXO3 density relative to FOXO3 in Figure 4D. (B) KMS-11 cells were treated with TAK-580 (20  $\mu$ M) alone or in combination with BTZ (10 nM) for 16 h. Whole-cell lysates were subjected to western blotting using phospho-AKT, AKT, and  $\beta$ -Actin Abs. (C) RPMI-8226 cells were treated with TAK-580 (20  $\mu$ M) alone or in combination with BTZ (10 nM) for 5 h. Whole-cell lysates were subjected to western blotting using CHOP and  $\beta$ -Actin Abs.